Prof. Dr. med. Antonio Pezzutto

Molecular Immunotherapy
Max-Delbrück Center for Molecular Medicine (MDC)
Robert-Rössle-Str. 10
13092 Berlin

University Education

  • 1972-1978 University of Padova Medical School, Padova, Italy
  • 1978-1982 University of Padova Medical School, Padova, Italy
  • 1983-1993 University of Heidelberg

Professional Experience (selection)

  • 1978-1982 Medical Resident, University of Padova Medical School
  • 1983-1993 Medical Resident, then Attending, University of Heidelberg
  • 1994-2001 Deputy Director, Hematology Oncology Berlin

Research Fields

  • Immunotherapy of Leukemia and Lymphoma

Selected References

  • Westermann, J., Flörcken, A., Willimsky, G., van Lessen, A., Kopp, J., Takvorian, A., Jöhrens, K., Lukowsky, A., Schönemann, C., Sawitzki, B., Pohla, H., Frank, R., Dörken, B., Schendel, D. J., Blankenstein, T. & Pezzutto, A. (2011). Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther, 4, 354-63
  • Westermann, J., Kopp, J., van Lessen, A., Hecker, A. C., Baskaynak, G., le Coutre, P., Döhner, K., Döhner, H., Dörken, B. & Pezzutto, A. (2007). Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol, 4, 297-306.
  • Westermann, J., Nguyen-Hoai, T., Baldenhofer, G., Höpken, U. E., Lipp, M., Dörken, B. & Pezzutto, A. (2007). CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther, 6, 523-32.